183 related articles for article (PubMed ID: 29540336)
41. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
42. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Laine L; Katz PO; Johnson DA; Ibegbu I; Goldstein MJ; Chou C; Rossiter G; Lu Y
Aliment Pharmacol Ther; 2011 Jan; 33(2):203-12. PubMed ID: 21114792
[TBL] [Abstract][Full Text] [Related]
43. [Rhabdomyolysis associated with long-term treatment of esomeprazole].
Nishikawa J; Hosokawa A; Fuchino M; Takatori S; Iwamoto M; Kashii Y; Bando T; Shimizu T; Minemura M; Sugiyama T
Nihon Shokakibyo Gakkai Zasshi; 2018; 115(3):299-304. PubMed ID: 29526982
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
45. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
[No Abstract] [Full Text] [Related]
46. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials.
Gralnek IM; Dulai GS; Fennerty MB; Spiegel BM
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1452-8. PubMed ID: 17162239
[TBL] [Abstract][Full Text] [Related]
47. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.
Fock KM; Teo EK; Ang TL; Chua TS; Ng TM; Tan YL
World J Gastroenterol; 2005 May; 11(20):3091-8. PubMed ID: 15918196
[TBL] [Abstract][Full Text] [Related]
48. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.
Kahrilas PJ; Falk GW; Johnson DA; Schmitt C; Collins DW; Whipple J; D'Amico D; Hamelin B; Joelsson B
Aliment Pharmacol Ther; 2000 Oct; 14(10):1249-58. PubMed ID: 11012468
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
[TBL] [Abstract][Full Text] [Related]
50. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2010 Nov; 51(5):593-8. PubMed ID: 20706150
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
[TBL] [Abstract][Full Text] [Related]
52. Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis.
Sun J; Yuan YZ; Hou XH; Zou DW; Lu B; Chen MH; Liu F; Wu KC; Zou XP; Li YQ; Zhou LY
World J Gastroenterol; 2015 Jun; 21(22):6965-73. PubMed ID: 26078574
[TBL] [Abstract][Full Text] [Related]
53. Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
Fock KM; Ang TL
Curr Opin Investig Drugs; 2008 Oct; 9(10):1108-15. PubMed ID: 18821474
[TBL] [Abstract][Full Text] [Related]
54. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
Liang CM; Kuo MT; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Wang HM; Yao CC; Tsai CE; Wang YK; Wang JW; Huang CF; Wu DC; Chuah SK;
World J Gastroenterol; 2017 Dec; 23(47):8395-8404. PubMed ID: 29307999
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.
Kinoshita Y; Hongo M;
Am J Gastroenterol; 2012 Apr; 107(4):522-30. PubMed ID: 22433921
[TBL] [Abstract][Full Text] [Related]
56. Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis.
Hsu WH; Kuo FC; Hu HM; Hsu PI; Wu DC; Kuo CH
Kaohsiung J Med Sci; 2015 May; 31(5):255-9. PubMed ID: 25910560
[TBL] [Abstract][Full Text] [Related]
57. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP; Wu TS; Dan YY
J Clin Pharm Ther; 2015 Aug; 40(4):368-75. PubMed ID: 25893507
[TBL] [Abstract][Full Text] [Related]
58. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
[TBL] [Abstract][Full Text] [Related]
59. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
Körner T; Schütze K; van Leendert RJ; Fumagalli I; Costa Neves B; Bohuschke M; Gatz G
Digestion; 2003; 67(1-2):6-13. PubMed ID: 12743434
[TBL] [Abstract][Full Text] [Related]
60. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis.
Baker R; Tsou VM; Tung J; Baker SS; Li H; Wang W; Rath N; Maguire MK; Comer GM
Clin Pediatr (Phila); 2010 Sep; 49(9):852-65. PubMed ID: 20522615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
